Personalized Medicine's Coming of Age: One Drug, One Patient Available to Purchase

A dendritic cell/myeloma fusion vaccine, given with lenalidomide and GM-CSF, did not result in a statistically significant increase in CR rates at 1 year posttransplant but was associated with a significant increase in circulating multiple myeloma–reactive lymphocytes indicative of tumor-specific immunity.

See related article by Chung et al., p. 4784